Skip to main content
S&P 5007,376.10-4.06%DOW51,651.46-3.19%NASDAQ24,396.69-5.21%BTC$75,968.00-5.30%ETH$2,248.70-7.21%GOLD$4,111.80+0.95%OIL$90.35+2.53%
Smart Investors Daily
SID Premium
GD

NASDAQ · GDTC

CytoMed Therapeutics Limited

Healthcare · Biotechnology

$0.89

Down-$0.06 (-6.63%)

Updated Nov 5, 2026, 7:23 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
19.36M
P/E ratio
-5.82
Dividend yield
0.00%
52-week range
$0.68 – $1.39
Volume
6.38K
Avg. volume
120.59K

Price performance · GDTC

GDTC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

GDTC closed at $0.89 after 21 trading sessions, down 9.29% for the selected period.

Last close
$0.89
Period change
-9.29%
Period low
$0.81
Period high
$0.98
Daily close
View OHLC price history
GDTC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$0.8309$0.8918$0.8309$0.8896.38K
Nov 3, 2026$0.92$0.92$0.852$0.915.18K
Nov 2, 2026$0.911$0.92$0.8551$0.909847.32K
Oct 30, 2026$0.888$0.9188$0.8292$0.918811.44K
Oct 29, 2026$0.8625$0.9297$0.85$0.900611.96K
Oct 28, 2026$0.82$0.935$0.82$0.93510.12K
Oct 27, 2026$0.89$0.935$0.85$0.8916.97K
Oct 26, 2026$0.90$0.94$0.845$0.926212.49K
Oct 23, 2026$0.8403$0.919$0.8403$0.9194.85K
Oct 22, 2026$0.875$0.919$0.8222$0.9195.91K
Oct 21, 2026$0.8108$0.919$0.8108$0.9194.99K
Oct 20, 2026$0.82$0.8715$0.8123$0.87158.28K
Oct 19, 2026$0.8501$0.865$0.8418$0.85215.01K
Oct 16, 2026$0.94$0.94$0.8401$0.87997.26K
Oct 15, 2026$0.8058$0.88$0.7303$0.879.48K
Oct 14, 2026$0.83$0.8659$0.81$0.859910.62K
Oct 13, 2026$0.865$0.88$0.8114$0.8726.66K
Oct 12, 2026$0.8406$0.9834$0.71$0.811454.76K
Oct 9, 2026$0.9385$0.94$0.853$0.8911.82K
Oct 8, 2026$0.90$0.945$0.90$0.944923.22K
Oct 7, 2026$0.90$0.98$0.80$0.9815.18K

Latest GDTC news

The latest Smart Investors Daily articles mentioning GDTC.

Stock researchCompany · Overview

GDTC research

Overview

Company profile and research snapshot.

Company profile

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
GDTC recent ratings
DateFirmRatingTarget
Oct 10, 2024BenchmarkSpeculative Buy—
Jun 11, 2024BenchmarkSpeculative Buy—
Dec 4, 2023BenchmarkSpeculative Buy—
Jul 21, 2023BenchmarkSpeculative Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 9, 2026

CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

SINGAPORE, Oct. 09, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the last

Benzinga · Oct 9, 2026

CytoMed Therapeutics Receives Nasdaq Noncompliance Notice

CytoMed Therapeutics Limited (the "Company") (NASDAQ:GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By